MCID: ACT010
MIFTS: 60

Acth-Secreting Pituitary Adenoma

Categories: Cancer diseases, Cardiovascular diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Acth-Secreting Pituitary Adenoma

MalaCards integrated aliases for Acth-Secreting Pituitary Adenoma:

Name: Acth-Secreting Pituitary Adenoma 12 20 44 15 70
Pituitary Acth Hypersecretion 43 6
Cushing Disease 20 43
Pituitary-Dependant Hypercortisolism Disorder 43
Pituitary-Dependent Cushing's Disease 70
Pituitary Corticotroph Micro-Adenoma 20
Pituitary Dependent Cushing Syndrome 20
Pituitary-Dependent Cushing Syndrome 20
Pituitary-Dependant Cushing Syndrome 43
Pituitary-Dependant Hypercortisolism 43
Adenoma, Pituitary, Acth-Secreting 39
Acth-Producing Pituitary Adenoma 12
Corticotroph Pituitary Adenoma 20
Adrenal Gland Hyperfunction 70
Pituitary Cushing Syndrome 43
Corticotroph Adenoma 12
Cushing's Disease 20
Cushing Syndrome 70
Corticotropinoma 12
Hypercortisolism 43

Classifications:



Summaries for Acth-Secreting Pituitary Adenoma

MedlinePlus Genetics : 43 Cushing disease is caused by elevated levels of a hormone called cortisol, which leads to a wide variety of signs and symptoms. This condition usually occurs in adults between the ages of 20 and 50; however, children may also be affected. The first sign of this condition is usually weight gain around the trunk and in the face. Affected individuals may get stretch marks (striae) on their thighs and abdomen and bruise easily. Individuals with Cushing disease can develop a hump on their upper back caused by abnormal deposits of fat. People with this condition can have muscle weakness, severe tiredness, and progressively thin and brittle bones that are prone to fracture (osteoporosis). They also have a weakened immune system and are at an increased risk of infections. Cushing disease can cause mood disorders such as anxiety, irritability, and depression. This condition can also affect a person's concentration and memory. People with Cushing disease have an increased chance of developing high blood pressure (hypertension) and diabetes. Women with Cushing disease may experience irregular menstruation and have excessive hair growth (hirsutism) on their face, abdomen, and legs. Men with Cushing disease may have erectile dysfunction. Children with Cushing disease typically experience slow growth.

MalaCards based summary : Acth-Secreting Pituitary Adenoma, also known as pituitary acth hypersecretion, is related to pituitary adenoma 4, acth-secreting and pituitary adenoma 1, multiple types, and has symptoms including cushingoid facies An important gene associated with Acth-Secreting Pituitary Adenoma is USP8 (Ubiquitin Specific Peptidase 8), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Metformin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal gland and bone, and related phenotypes are failure to thrive and lipodystrophy

Disease Ontology : 12 A functioning pituitary adenoma that characterized by excess cortisol a primary cause of Cushing's syndrome.

GARD : 20 ACTH-secreting pituitary adenoma is a condition characterized by elevated levels of a hormone called cortisol secreted by a tumor in the pituitary gland. It is part of a group of diseases that cause Cushing's syndrome, characterized by signs and symptoms that may include weight gain around the trunk and in the face, stretch marks, easy bruising, a hump on the upper back, muscle weakness, tiredness, thin bones that are prone to fracture ( osteoporosis ), mood disorders and memory problems, as well as an increased risk of infections, high blood pressure and diabetes. Women may have irregular menses and a lot of hair in the body (hirsutism). It occurs when a benign pituitary tumor (adenoma) or pituitary hyperplasia causes the adrenal glands to produce large amounts of cortisol. Some cases are caused by somatic mutations in the AIP and the GNAS genes. Rarely, an ACTH-secreting pituitary adenoma can be inherited, either as an isolated condition or as part of a genetic syndrome (such as multiple endocrine neoplasia type 1 (MEN1) and familial isolated pituitary adenoma ), but most cases are sporadic. Treatment generally involves surgery to remove the tumor and medications to decrease cortisol levels.

Wikipedia : 73 Cushing's syndrome is the collection of signs and symptoms due to prolonged exposure to glucocorticoids... more...

Related Diseases for Acth-Secreting Pituitary Adenoma

Diseases in the Acth-Secreting Pituitary Adenoma family:

Pituitary Adenoma 4, Acth-Secreting

Diseases related to Acth-Secreting Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 547)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 4, acth-secreting 32.6 USP8 GNAI2 AIP
2 pituitary adenoma 1, multiple types 32.2 SST PRL MEN1 AIP
3 adrenal cortical adenoma 32.2 PRKAR1A POMC MEN1
4 acth-independent macronodular adrenal hyperplasia 32.2 PRKAR1A POMC CRH
5 familial isolated pituitary adenoma 32.1 MEN1 AIP
6 hypopituitarism 30.8 TBX19 PRL POMC CRH
7 chromophobe adenoma 30.8 PRL POMC
8 adenoma 30.7 USP8 SSTR5 SSTR2 SST PRL PRKAR1A
9 diabetes insipidus 30.7 PRL POMC CRH
10 amenorrhea 30.7 PRL POMC CRH
11 mental depression 30.7 POMC NR3C1 MIR24-1 CRH
12 basophil adenoma 30.7 PRKAR1A POMC
13 neuroendocrine tumor 30.7 SSTR2 SST POMC MEN1
14 pituitary tumors 30.6 SSTR5 SST PRL POMC MEN1 AIP
15 pituitary adenoma 30.6 USP8 SSTR5 SSTR2 SST PRL PRKAR1A
16 insulin-like growth factor i 30.6 SST PRL IGFBP6
17 depression 30.6 PRL NR3C1 CRH
18 hypothyroidism, congenital, nongoitrous, 4 30.5 PRL POMC
19 pituitary apoplexy 30.5 SST PRL POMC MEN1 AIP
20 hypokalemia 30.5 POMC NR3C1 CRH
21 endogenous depression 30.5 PRL POMC NR3C1 CRH
22 major depressive disorder 30.5 SST PRL POMC NR3C1 CRH
23 mccune-albright syndrome 30.5 SST PRL PRKAR1A MEN1
24 hyperthyroidism 30.4 SST PRL POMC
25 hyperprolactinemia 30.4 SST PRL POMC
26 lymphocytic hypophysitis 30.4 TBX19 POMC
27 pituitary carcinoma 30.3 SSTR2 SST PRL POMC MIR93 MEN1
28 nelson syndrome 30.3 USP8 SSTR5 SST PRL POMC NR3C1
29 multiple endocrine neoplasia 30.3 SST PRKAR1A POMC MEN1 AIP
30 meningioma, familial 30.3 SSTR5 SSTR2 SST PRKAR1A MEN1
31 tuberculum sellae meningioma 30.3 PRL POMC
32 adrenal adenoma 30.3 PRKAR1A POMC MEN1 CRH
33 carcinoid syndrome 30.3 SST MEN1
34 gangliocytoma 30.2 PRL POMC CRH
35 acute stress disorder 30.2 POMC NR3C1 CRH
36 conn's syndrome 30.2 SST PRL PRKAR1A POMC NR3C1 MEN1
37 thyroid gland medullary carcinoma 30.2 SSTR2 SST POMC MEN1
38 pituitary-dependent cushing's disease 30.2 USP8 SST PRL POMC NR3C1 CRH
39 sheehan syndrome 30.2 PRL POMC CRH
40 melancholia 30.2 PRL POMC CRH
41 oncogenic osteomalacia 30.2 SSTR5 SSTR1
42 atypical depressive disorder 30.2 POMC NR3C1 CRH
43 gigantism 30.2 PRL GPR101 AIP
44 ectopic cushing syndrome 30.2 TBX19 SST PRL POMC NR3C1 CRH
45 breast ductal adenoma 30.2 PRL PRKAR1A
46 sleep disorder 30.1 PRL POMC CRH
47 post-traumatic stress disorder 30.1 POMC NR3C1 CRH
48 primary pigmented nodular adrenocortical disease 30.1 SSTR1 PRKAR1A POMC NR3C1 MEN1 GPR101
49 carcinoid tumors, intestinal 30.1 SSTR2 SST MEN1
50 thyroid gland disease 30.1 SST PRL POMC

Graphical network of the top 20 diseases related to Acth-Secreting Pituitary Adenoma:



Diseases related to Acth-Secreting Pituitary Adenoma

Symptoms & Phenotypes for Acth-Secreting Pituitary Adenoma

Human phenotypes related to Acth-Secreting Pituitary Adenoma:

31 (show all 40)
# Description HPO Frequency HPO Source Accession
1 failure to thrive 31 hallmark (90%) HP:0001508
2 lipodystrophy 31 hallmark (90%) HP:0009125
3 round face 31 hallmark (90%) HP:0000311
4 truncal obesity 31 hallmark (90%) HP:0001956
5 thin skin 31 hallmark (90%) HP:0000963
6 adrenal hyperplasia 31 hallmark (90%) HP:0008221
7 pituitary adenoma 31 hallmark (90%) HP:0002893
8 depressivity 31 frequent (33%) HP:0000716
9 diabetes mellitus 31 frequent (33%) HP:0000819
10 hypertension 31 frequent (33%) HP:0000822
11 hypokalemia 31 frequent (33%) HP:0002900
12 fatigue 31 frequent (33%) HP:0012378
13 immunodeficiency 31 frequent (33%) HP:0002721
14 acne 31 frequent (33%) HP:0001061
15 osteoporosis 31 frequent (33%) HP:0000939
16 anxiety 31 frequent (33%) HP:0000739
17 nephrolithiasis 31 frequent (33%) HP:0000787
18 recurrent fractures 31 frequent (33%) HP:0002757
19 generalized hirsutism 31 frequent (33%) HP:0002230
20 bruising susceptibility 31 frequent (33%) HP:0000978
21 infertility 31 frequent (33%) HP:0000789
22 metrorrhagia 31 frequent (33%) HP:0100608
23 menorrhagia 31 frequent (33%) HP:0000132
24 sleep disturbance 31 occasional (7.5%) HP:0002360
25 cataract 31 occasional (7.5%) HP:0000518
26 avascular necrosis 31 occasional (7.5%) HP:0010885
27 myopathy 31 occasional (7.5%) HP:0003198
28 premature ovarian insufficiency 31 occasional (7.5%) HP:0008209
29 venous thrombosis 31 occasional (7.5%) HP:0004936
30 abdominal pain 31 occasional (7.5%) HP:0002027
31 telangiectasia of the skin 31 occasional (7.5%) HP:0100585
32 bipolar affective disorder 31 occasional (7.5%) HP:0007302
33 headache 31 occasional (7.5%) HP:0002315
34 generalized hyperpigmentation 31 occasional (7.5%) HP:0007440
35 psychosis 31 occasional (7.5%) HP:0000709
36 lethargy 31 occasional (7.5%) HP:0001254
37 cardiomyopathy 31 occasional (7.5%) HP:0001638
38 visual loss 31 occasional (7.5%) HP:0000572
39 recurrent skin infections 31 occasional (7.5%) HP:0001581
40 onychomycosis 31 occasional (7.5%) HP:0012203

UMLS symptoms related to Acth-Secreting Pituitary Adenoma:


cushingoid facies

MGI Mouse Phenotypes related to Acth-Secreting Pituitary Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.06 AIP CRH GNAI2 GPR101 MEN1 NR3C1
2 endocrine/exocrine gland MP:0005379 10 AIP CRH GNAI2 MEN1 NR3C1 POMC
3 liver/biliary system MP:0005370 9.65 AIP CRH GNAI2 MEN1 NR3C1 POMC
4 nervous system MP:0003631 9.36 CRH GNAI2 MEN1 NR3C1 POMC PRKCD

Drugs & Therapeutics for Acth-Secreting Pituitary Adenoma

Drugs for Acth-Secreting Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Liraglutide Approved Phase 4 204656-20-2 44147092
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4 Sitagliptin Phosphate Phase 4
5 Dipeptidyl-Peptidase IV Inhibitors Phase 4
6 Incretins Phase 4
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Cabergoline Approved Phase 3 81409-90-7 54746
9 Orange Approved Phase 3
10
Metyrapone Approved, Investigational Phase 3 54-36-4 4174
11
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
12 Neurotransmitter Agents Phase 3
13 Dopamine Agents Phase 3
14 Dopamine agonists Phase 3
15 Antiparkinson Agents Phase 3
16 Pharmaceutical Solutions Phase 3
17 Antimetabolites Phase 3
18 glucocorticoids Phase 3
19 Melanocyte-Stimulating Hormones Phase 3
20 beta-Endorphin Phase 3
21
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
22
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
23
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
24
Iron Approved Phase 2 7439-89-6 23925 29936
25
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
26
Pentetic acid Approved Phase 2 67-43-6
27
Levodopa Approved Phase 2 59-92-7 6047
28
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
31
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
32
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
33
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
34
Octreotide Approved, Investigational Phase 1, Phase 2 83150-76-9 383414 6400441
35
Mitotane Approved Phase 2 53-19-0 4211
36
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
37
Racepinephrine Approved Phase 2 329-65-7 838
38
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
39
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
40
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
41
Somatostatin Approved, Investigational Phase 2 51110-01-1, 38916-34-6 53481605
42
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
43
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
44
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
45
Maleic acid Experimental Phase 2 110-16-7 444266
46 Vasodilator Agents Phase 2
47 Phosphodiesterase Inhibitors Phase 2
48 Phosphodiesterase 5 Inhibitors Phase 2
49 Anticoagulants Phase 2
50 Fluorodeoxyglucose F18 Phase 2

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
2 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
3 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4 Mifepristone
4 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
5 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
6 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
7 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
8 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
9 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
10 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
11 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
12 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
13 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
14 An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
15 An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
16 Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks Completed NCT02297945 Phase 3 metyrapone
17 An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome Completed NCT01838551 Phase 3 Levoketoconazole
18 A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Completed NCT03277690 Phase 3 Levoketoconazole;Placebo
19 Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant Recruiting NCT04308590 Phase 3 relacorilant
20 Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant Recruiting NCT03697109 Phase 3 Relacorilant
21 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Active, not recruiting NCT03621280 Phase 3 Levoketoconazole
22 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
23 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
24 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
25 Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome Unknown status NCT02611258 Phase 2 Tadalafil
26 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
27 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
28 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
29 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
30 New Imaging Modalities in the Evaluation of Patients With Ectopic Cushing's Syndrome Completed NCT00001849 Phase 2 Pentetreotide;18F-DOPA;18-FDG
31 Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
32 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Recruiting NCT04339751 Phase 2 Vorinostat
33 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
34 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
35 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
36 Evaluation of 68Ga -DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome Recruiting NCT02019706 Phase 1, Phase 2
37 An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat Recruiting NCT03606408 Phase 2 osilodrostat
38 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
39 An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome Enrolling by invitation NCT03604198 Phase 2 relacorilant
40 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
41 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
42 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Terminated NCT01915303 Phase 2 Pasireotide with or without cabergoline
43 A Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Who Have Previously Undergone or Are Not Candidates for Additional Surgery or Radiation Terminated NCT00813592 Phase 2 SOM230B
44 Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
45 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome Terminated NCT03053271 Phase 2 ATR-101;Placebo
46 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone
47 An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
48 A Proof of Concept and Open-label Study to Test the Efficacy and Safety of Pasireotide in Patients With Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
49 Cognitive Sequels of Cushing Syndrome Unknown status NCT02603653
50 Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015 Unknown status NCT03297892

Search NIH Clinical Center for Acth-Secreting Pituitary Adenoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aminoglutethimide
Fludrocortisone
fluorocortisol acetate
Mitotane
pasireotide

Cochrane evidence based reviews: acth-secreting pituitary adenoma

Genetic Tests for Acth-Secreting Pituitary Adenoma

Anatomical Context for Acth-Secreting Pituitary Adenoma

MalaCards organs/tissues related to Acth-Secreting Pituitary Adenoma:

40
Pituitary, Adrenal Gland, Bone, Liver, Thyroid, Heart, Skin

Publications for Acth-Secreting Pituitary Adenoma

Articles related to Acth-Secreting Pituitary Adenoma:

(show top 50) (show all 135)
# Title Authors PMID Year
1
The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. 6
25942478 2015
2
Recurrent gain-of-function USP8 mutations in Cushing's disease. 6
25675982 2015
3
G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. 6
7737262 1995
4
Comprehensive Diagnosis and Surgical Management of Cushing Disease: Two-Dimensional Angiographic and Operative Video. 61
33484885 2021
5
Stereotactic radiosurgery before bilateral adrenalectomy is associated with lowered risk of Nelson's syndrome in refractory Cushing's disease patients. 61
33759014 2021
6
Outcomes of endoscopic transsphenoidal surgery for Cushing's disease. 61
33658018 2021
7
A human ACTH-secreting corticotroph tumoroid model: Novel Human ACTH-Secreting Tumor Cell in vitro Model. 61
33773184 2021
8
Gamma knife radiosurgery in patients with Nelson's syndrome. 61
33611756 2021
9
Assessment of non-traumatic vertebral fractures in Cushing's syndrome patients. 61
33420960 2021
10
Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease. 61
33143437 2020
11
Nail hyperpigmentation in ACTH-secreting pituitary adenoma (Cushing's disease) and its resolution after successful trans-sphenoidal excision. 61
32303530 2020
12
Long-term follow-up for ectopic ACTH-secreting pituitary adenoma in a single tertiary medical center and a literature review. 61
31838612 2020
13
ACTH-Cell Pituitary Adenoma With Signet Ring Cells: A Rare Case Report and Review of The Literature. 61
32044887 2020
14
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. 61
31702999 2020
15
SPONTANEOUS RESOLUTION OF PRIMARY HYPERCORTISOLISM OF CUSHING DISEASE AFTER PITUITARY HEMORRHAGE. 61
32984518 2020
16
Synchronous bilateral adrenalectomy in ACTH-dependent hypercortisolism: predictors, biomarkers and outcomes. 61
31583577 2019
17
The coexistence of infundibular pituicytoma and Cushing's disease due to pituitary adenoma: A case report. 61
31734654 2019
18
[Surgical treatment for Cushing's disease with negative results in high dose dexamethasone suppression tests]. 61
31137142 2019
19
Recovery of Adrenal Function after Pituitary Surgery in Patients with Cushing Disease: Persistent Remission or Recurrence? 61
30636245 2019
20
Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies. 61
30187173 2018
21
Invasive ACTH-secreting pituitary macroadenoma in remission after transsphenoidal resection: A case report and literature review. 61
30431585 2018
22
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. 61
30085142 2018
23
Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles. 61
29920815 2018
24
Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs. 61
29864631 2018
25
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. 61
29143885 2018
26
Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenoma Localized by 18F-Choline PET/CT. 61
29189371 2018
27
Integration of Proteomics and Metabolomics Revealed Metabolite-Protein Networks in ACTH-Secreting Pituitary Adenoma. 61
30532734 2018
28
Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma. 61
28005257 2017
29
A retrospective review of 34 cases of pediatric pituitary adenoma. 61
28721598 2017
30
Cryptococcal meningitis after transnasal transsphenoidal pituitary microsurgery of ACTH-secreting pituitary adenoma: A case report. 61
28700464 2017
31
Endoscopic Endonasal Surgery for Remission of Cushing Disease Caused by Ectopic Intracavernous Macroadenoma: Case Report and Literature Review. 61
28003168 2017
32
Cushing's disease: pathobiology, diagnosis, and management. 61
27104844 2017
33
Bone morphogenetic protein 4 and bone morphogenetic protein receptor expression in the pituitary gland of adult dogs in healthy condition and with ACTH-secreting pituitary adenoma. 61
26542941 2017
34
Case of diabetic ketoacidosis as an initial presentation of Cushing's syndrome. 61
28458895 2017
35
Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing's Syndromes Treatment: Case Presentations. 61
29375480 2017
36
Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis. 61
27690016 2016
37
Cushing in a Leaf: Endocrine Disruption From a Natural Remedy. 61
27218272 2016
38
[Retrospective analysis to evaluate efficacy and safety of stereotactic radiosurgery in Cushing's disease: 24 cases and a review]. 61
27020252 2016
39
Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome. 61
26833215 2016
40
Systemic Sarcoidosis Unmasked by Cushing's Disease Surgical Treatment. 61
27525010 2016
41
Correction: Lycopene and Beta-Carotene Induce Growth Inhibition and Proapoptotic Effects on ACTH-Secreting Pituitary Adenoma Cells. 61
26848958 2016
42
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells. 61
26522132 2016
43
Cushing's Disease - Quality of Life, Recurrence and Long-term Morbidity. 61
29632565 2015
44
Cushing's disease: predicting long-term remission after surgical treatment. 61
25639315 2015
45
Cushing's disease: current medical therapies and molecular insights guiding future therapies. 61
25639313 2015
46
Cyclic Cushing's disease with misleading inferior petrosal sinus sampling results during a trough phase. 61
25639325 2015
47
Ectopic ACTH-secreting pituitary adenoma of the sphenoid sinus: case report of endoscopic endonasal resection and systematic review of the literature. 61
25639312 2015
48
Progression of an Invasive ACTH Pituitary Macroadenoma with Cushing's Disease to Pituitary Carcinoma. 61
26366311 2015
49
[ACTH's ectopic secretion in a patient with precedents of Cushing's disease]. 61
26339876 2015
50
Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth. 61
24379119 2014

Variations for Acth-Secreting Pituitary Adenoma

ClinVar genetic disease variations for Acth-Secreting Pituitary Adenoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 GNAI2 NM_002070.4(GNAI2):c.535C>G (p.Arg179Gly) SNV Pathogenic 15905 rs137853226 GRCh37: 3:50293694-50293694
GRCh38: 3:50256262-50256262
2 USP8 NM_005154.5(USP8):c.2152_2154TCC[1] (p.Ser719del) Microsatellite Pathogenic 161991 rs672601306 GRCh37: 15:50782639-50782641
GRCh38: 15:50490442-50490444
3 USP8 NM_005154.5(USP8):c.2152T>C (p.Ser718Pro) SNV Pathogenic 161992 rs672601307 GRCh37: 15:50782640-50782640
GRCh38: 15:50490443-50490443
4 USP8 NM_005154.5(USP8):c.2153C>G (p.Ser718Cys) SNV Pathogenic 161993 rs672601308 GRCh37: 15:50782641-50782641
GRCh38: 15:50490444-50490444
5 USP8 NM_005154.5(USP8):c.2138T>G (p.Leu713Arg) SNV Pathogenic 161994 rs672601309 GRCh37: 15:50782626-50782626
GRCh38: 15:50490429-50490429
6 USP8 NM_005154.5(USP8):c.2159C>G (p.Pro720Arg) SNV Pathogenic 161995 rs672601311 GRCh37: 15:50782647-50782647
GRCh38: 15:50490450-50490450
7 AIP NM_003977.4(AIP):c.911G>A (p.Arg304Gln) SNV Pathogenic 4893 rs104894190 GRCh37: 11:67258382-67258382
GRCh38: 11:67490911-67490911
8 AIP NM_003977.4(AIP):c.26G>A (p.Arg9Gln) SNV Uncertain significance 485052 rs139459091 GRCh37: 11:67250655-67250655
GRCh38: 11:67483184-67483184
9 AIP NM_003977.4(AIP):c.827C>T (p.Ala276Val) SNV Uncertain significance 485056 rs61741147 GRCh37: 11:67258298-67258298
GRCh38: 11:67490827-67490827

Cosmic variations for Acth-Secreting Pituitary Adenoma:

9 (show top 50) (show all 242)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88531076 USP8 pituitary,NS,adenoma,ACTH c.2159C>A p.P720Q 15:50490450-50490450 51
2 COSM88530729 USP8 pituitary,NS,adenoma,ACTH c.2155T>C p.S719P 15:50490446-50490446 51
3 COSM98895036 USP8 pituitary,NS,adenoma,ACTH c.2147C>A p.S716Y 15:50490438-50490438 51
4 COSM88530892 USP8 pituitary,NS,adenoma,ACTH c.2152T>C p.S718P 15:50490443-50490443 51
5 COSM109780485 USP8 pituitary,NS,adenoma,ACTH c.1841C>A p.P614Q 15:50490450-50490450 51
6 COSM109780387 USP8 pituitary,NS,adenoma,ACTH c.1834T>C p.S612P 15:50490443-50490443 51
7 COSM98887708 USP8 pituitary,NS,adenoma,ACTH c.2152T>C p.S718P 15:50490443-50490443 51
8 COSM88531498 USP8 pituitary,NS,adenoma,ACTH c.2159C>G p.P720R 15:50490450-50490450 51
9 COSM98888470 USP8 pituitary,NS,adenoma,ACTH c.2159C>G p.P720R 15:50490450-50490450 51
10 COSM88536071 USP8 pituitary,NS,adenoma,ACTH c.2147C>T p.S716F 15:50490438-50490438 51
11 COSM98887452 USP8 pituitary,NS,adenoma,ACTH c.2155T>C p.S719P 15:50490446-50490446 51
12 COSM109785555 USP8 pituitary,NS,adenoma,ACTH c.1829C>A p.S610Y 15:50490438-50490438 51
13 COSM109780828 USP8 pituitary,NS,adenoma,ACTH c.1841C>G p.P614R 15:50490450-50490450 51
14 COSM109784031 USP8 pituitary,NS,adenoma,ACTH c.1829C>T p.S610F 15:50490438-50490438 51
15 COSM109780255 USP8 pituitary,NS,adenoma,ACTH c.1837T>C p.S613P 15:50490446-50490446 51
16 COSM88533412 USP8 pituitary,NS,adenoma,ACTH c.2153C>T p.S718F 15:50490444-50490444 51
17 COSM88538415 USP8 pituitary,NS,adenoma,ACTH c.2147C>A p.S716Y 15:50490438-50490438 51
18 COSM98890346 USP8 pituitary,NS,adenoma,ACTH c.2153C>T p.S718F 15:50490444-50490444 51
19 COSM98892851 USP8 pituitary,NS,adenoma,ACTH c.2147C>T p.S716F 15:50490438-50490438 51
20 COSM109782146 USP8 pituitary,NS,adenoma,ACTH c.1835C>T p.S612F 15:50490444-50490444 51
21 COSM98888036 USP8 pituitary,NS,adenoma,ACTH c.2159C>A p.P720Q 15:50490450-50490450 51
22 COSM94026628 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 51
23 COSM94004581 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 51
24 COSM94129750 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 51
25 COSM94074224 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 51
26 COSM86764249 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 51
27 COSM86624499 RB1 pituitary,NS,adenoma,ACTH-FSH-GH-LH-PRL c.1861C>A p.R621S 13:48456250-48456250 51
28 COSM87137804 PIK3CA pituitary,NS,adenoma,ACTH c.3026G>A p.G1009E 3:179234183-179234183 51
29 COSM148937795 PIK3CA pituitary,NS,adenoma,ACTH c.*106G>A p.? 3:179234183-179234183 51
30 COSM87180985 PIK3CA pituitary,NS,adenoma,ACTH c.2984C>A p.A995D 3:179234141-179234141 51
31 COSM148978035 PIK3CA pituitary,NS,adenoma,ACTH c.*64C>A p.? 3:179234141-179234141 51
32 COSM100205339 MEN1 pituitary,NS,adenoma,ACTH c.1186-338C>A p.? 11:64805154-64805154 51
33 COSM100256750 MEN1 pituitary,NS,adenoma,ACTH c.1230C>A p.F410L 11:64805154-64805154 51
34 COSM100175300 MEN1 pituitary,NS,adenoma,ACTH c.1245C>A p.F415L 11:64805154-64805154 51
35 COSM92073850 MEN1 pituitary,NS,adenoma,ACTH c.1245C>A p.F415L 11:64805154-64805154 51
36 COSM100245522 MEN1 pituitary,NS,adenoma,ACTH c.1125C>A p.F375L 11:64805154-64805154 51
37 COSM99577182 MEN1 pituitary,NS,adenoma,ACTH c.1245C>A p.F415L 11:64805154-64805154 51
38 COSM90431218 MEN1 pituitary,NS,adenoma,ACTH c.1230C>A p.F410L 11:64805154-64805154 51
39 COSM92201949 MEN1 pituitary,NS,adenoma,ACTH c.1230C>A p.F410L 11:64805154-64805154 51
40 COSM99565357 MEN1 pituitary,NS,adenoma,ACTH c.1245C>A p.F415L 11:64805154-64805154 51
41 COSM105721542 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 51
42 COSM101967380 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 51
43 COSM91331304 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 51
44 COSM112988978 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 51
45 COSM101951743 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 51
46 COSM87643479 GNAS pituitary,NS,adenoma,ACTH c.94-226A>G p.? 20:58909541-58909541 51
47 COSM85346567 GNAS pituitary,NS,adenoma,ACTH c.635A>G p.Q212R 20:58909541-58909541 51
48 COSM93760866 GNAS pituitary,NS,adenoma,ACTH c.2530C>T p.R844C 20:58909365-58909365 51
49 COSM93086636 GNAS pituitary,NS,adenoma,ACTH c.604C>T p.R202C 20:58909365-58909365 51
50 COSM93761837 GNAS pituitary,NS,adenoma,ACTH c.2609A>G p.Q870R 20:58909541-58909541 51

Expression for Acth-Secreting Pituitary Adenoma

Search GEO for disease gene expression data for Acth-Secreting Pituitary Adenoma.

Pathways for Acth-Secreting Pituitary Adenoma

Pathways related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 USP8 SSTR5 SSTR2 SSTR1 SST PRKCD
2
Show member pathways
13.3 SSTR5 SSTR2 SSTR1 SST PRL POMC
3
Show member pathways
12.59 PRL PRKCD PRKAR1A NR3C1 GNAI2
4
Show member pathways
12.57 USP8 POMC MEN1 GNAI2 CRH AIP
5
Show member pathways
12.39 PRKCD PRKAR1A POMC GNAI2 CRH
6
Show member pathways
12.31 PRKCD PRKAR1A POMC GNAI2
7
Show member pathways
12.14 PRKCD PRKAR1A IGFBP6 GNAI2 CRH
8 11.77 SSTR5 SSTR2 SSTR1 SST POMC GNAI2
9 11.76 SSTR2 SSTR1 SST PRKAR1A NR3C1
10 11.55 PRL POMC NR3C1
11 10.99 TBX19 PRKCD POMC GNAI2 CRH
12 10.28 POMC CRH

GO Terms for Acth-Secreting Pituitary Adenoma

Biological processes related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.97 SSTR5 SSTR2 SSTR1 SST POMC GPR101
2 signal transduction GO:0007165 9.9 SSTR5 SSTR2 SSTR1 PRL PRKCD POMC
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.63 SSTR5 SSTR2 SSTR1
4 neuropeptide signaling pathway GO:0007218 9.62 SSTR5 SSTR2 SSTR1 POMC
5 cellular response to dexamethasone stimulus GO:0071549 9.58 USP8 NR3C1 CRH
6 negative regulation of cell proliferation GO:0008285 9.5 SSTR5 SSTR2 SSTR1 SST MIR93 MEN1
7 regulation of protein kinase A signaling GO:0010738 9.48 PRKAR1A AIP
8 hormone-mediated apoptotic signaling pathway GO:0008628 9.43 SST CRH
9 cellular response to glucocorticoid stimulus GO:0071385 9.43 SSTR5 SSTR2 NR3C1
10 somatostatin signaling pathway GO:0038170 8.8 SSTR5 SSTR2 SSTR1

Molecular functions related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.46 SST PRL POMC CRH
2 peptide binding GO:0042277 9.43 SSTR5 SSTR2 SSTR1
3 neuropeptide binding GO:0042923 9.13 SSTR5 SSTR2 SSTR1
4 somatostatin receptor activity GO:0004994 8.8 SSTR5 SSTR2 SSTR1

Sources for Acth-Secreting Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....